TL;DR
- •Financial advisors carry fiduciary responsibility for clients' life savings — a level of accountability that produces sustained stress, anxiety, and depression at rates above salaried professions.
- •Market volatility produces sympathetic-nervous-system activation in real-time as clients' portfolios move, with no off-switch during business hours.
- •FINRA / Form U4 disclosure requirements create real concerns about reporting mental-health treatment, even though standard outpatient care typically doesn't require disclosure.
- •Tovani is direct-pay ($349/month, HSA/FSA eligible) — no insurance claim, no employer EAP record, no health plan tied to your firm or independent business.
- •For treatment-resistant cases where standard antidepressants and therapy haven't produced enough response, ketamine's NMDA/glutamate mechanism is a different approach with rapid onset and no chronic medication burden.
- •Most advisor-patients say what mattered most was: discretion and privacy from compliance, FINRA, and clients; same physician every visit; ability to maintain client-facing function during treatment; complete separation from any firm health records.
The stressors specific to your work
- •Fiduciary responsibility for clients' life savings — high-stakes accountability
- •Real-time market exposure during business hours with continuous portfolio volatility
- •Compliance and audit pressure layered on top of client relationship demands
- •Long hours and entertainment culture that displaces sleep and recovery time
- •High-income lifestyle pressures (housing, schools, travel) tied to maintaining performance
- •Industry stigma around mental-health concerns despite high prevalence
Why telehealth works for financial advisors
- •Sessions scheduled outside market hours — evenings or weekends
- •No clinic visits — fits between client meetings and after-market wrap-up
- •Treatment at home or office — completely private from clients and compliance
- •Same physician every visit — continuity matters when bandwidth is scarce
- •Compatible with frequent travel within FL/NJ residency
Privacy considerations
- •Tovani is direct-pay — no insurance claim tied to firm health plan or compliance records
- •Patient records are NEVER visible to your firm, compliance department, FINRA, SEC, or any regulatory body without your explicit authorization
- •FINRA Form U4 / U5 disclosure questions ask about specific events (involuntary commitment, certain custodial situations) — standard outpatient mental-health treatment typically does NOT require disclosure
- •For independent RIAs and dually-registered advisors, the same private medical-record protections apply
- •Discuss any specific licensing concerns with a securities attorney if you're unsure — but standard outpatient depression and anxiety treatment is generally not a reportable event
5-minute screening · Reviewed by a board-certified physician · FL & NJ · $349/month
Frequently asked
Will my firm or compliance find out?
No. Tovani is a private medical practice with HIPAA protections. Your treatment is not visible to your firm, compliance department, FINRA, SEC, or any regulatory body. There is no insurance claim, no employer EAP involvement, and no industry-database reporting.
Do I have to disclose this on Form U4?
In most cases, no. FINRA Form U4 / U5 disclosure questions ask about specific events (involuntary psychiatric commitment, certain custodial or fiduciary determinations) — standard outpatient depression or anxiety treatment is generally NOT a reportable event. If you have specific concerns, consult a securities attorney before starting any treatment.
Can I take a ketamine session during market hours?
Not recommended. Dissociative effects last 1-2 hours during the dosing period plus recovery time. Most advisor-patients schedule sessions after market close (evenings) or on weekends. By the next morning you're fully able to monitor markets, take client calls, and handle compliance responsibilities.
I'm worried being on antidepressants will affect my judgment around client investments.
Common concern, and the answer is reassuring: well-controlled depression and anxiety produce BETTER decision-making than the untreated condition. The cognitive cost of untreated depression (rumination, indecision, distorted risk assessment) exceeds the cost of treatment for nearly all patients. Many advisors find their judgment sharpens after treatment because the cognitive burden of untreated symptoms is removed.
I've tried SSRIs and they helped depression but blunted my drive. What now?
A common pattern in high-performers. Options to discuss with your prescriber: switching to Wellbutrin (NDRI, doesn't blunt drive the way SSRIs can), combining Wellbutrin with your existing SSRI, or — for patients who want to leave the SSRI class entirely — mechanism-switching to ketamine. Many high-performer patients report restored drive and ambition during ketamine treatment alongside the mood lift.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — relevant for high-functioning patients in demanding professions who maintain external performance while internal symptoms persist. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — addresses clinical guidance for patients who have not responded to first-line treatments. PMID 28249076